A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2017
At a glance
- Drugs RGX 314 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors REGENXBIO
- 20 Sep 2017 According to a REGENXBIO media release, the company plans to share an interim trial update by the end of 2017.
- 20 Sep 2017 According to a REGENXBIO media release, the first cohort of six patients has been dosed in the trial. All six study sites are active to support enrollment in the next dose cohort that is projected to start after review by the Data Safety Monitoring Board this month.
- 23 Mar 2017 Status changed from not yet recruiting to recruiting.